[Current status of prostate cancer screening research]

Prostate cancer is the second most common malignant tumor among men worldwide. Its early diagnosis relies on screening. How to increase the detection rate of clinically significant prostate cancer, avoid overdiagnosis and over-treatment of low-risk tumors, while also considering economic benefits, has become a core issue in the field of screening. Currently, international prostate cancer screening strategies are moving from a single prostate-specific antigen (PSA) screening to individualized risk stratification, and exploring the roles of various stratification tools, such as magnetic resonance imaging (MRI), new biomarkers, and risk prediction models. However, there is no universally recognized unified approach. In recent years, although the incidence of prostate cancer in China has increased rapidly, the early diagnosis rate is still low. This is directly related to the insufficient prevalence of prostate cancer screening in China. Moreover, China also faces problems such as the lack of a reasonable screening model for elderly high-risk populations, insufficient public awareness, and the absence of a refined screening path. Future work involves building stratified screening strategies suitable for the Chinese population based on Chinese data, promoting the transition of screening from opportunistic to systematic, and is a task that needs to be carried out.